Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-23, Stock:NVS, The news for the past five days is as follows:
2018-01-16: NEWS1: 3 Biotech Stocks Start Healthy in '18: Will the Rally Last?.NEWS2: Stock Gains Vanish As Small Caps Reverse Lower.NEWS3: Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?.NEWS4: Novartis (NVS) Announces Acceptance of Humira BLA by the FDA.NEWS5: How Teva Pharmaceutical Plans to Improve Financial Profile.NEWS6: Novartis (NVS) Announces Acceptance of Humira BLA by the FDA.NEWS7: The Swiss Stock Market Fell Again As Roche Weighs.NEWS8: European Markets Finished Mixed Despite Dip In Euro.NEWS9: European Shares Inch Higher As Euro Rally Pauses.NEWS10: Sandoz: FDA To Review BLA For Proposed Biosimilar Adalimumab - Quick Facts.NEWS11: The Race To Find A Treatment For NASH.
2018-01-17: NEWS1: Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense.NEWS2: Why Celgene&apos;s Rumored Acquisition Of Juno Actually Makes Sense.NEWS3: Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients.NEWS4: Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline.NEWS5: Teva Pharmaceutical: Still Focused on New Product Launches.NEWS6: Novartis's Kymriah wins speedy reviews in U.S., Europe.NEWS7: Novartis Reports FDA Priority Review For Kymriah - Quick Facts.NEWS8: Juno Therapeutics Stock Rockets On Report That Celgene Is In Buyout Talks.
2018-01-18: NEWS1: Sensex, Nifty Marginally Higher In Early Trade.NEWS2: 3 Biotech Stocks Start Healthy in ’18: Will the Rally Last?.NEWS3: Juno Hits 52-Week High on Celgene's Rumored Buyout Interest.NEWS4: Merck & Co.’s Business Segments and Performance in 3Q17.NEWS5: 3 Top-Ranked Drug Stocks That Are Broker Favorites.NEWS6: 3 Biotech Stocks Start Healthy in ’18: Will the Rally Last?.NEWS7: Why Opdivo Could Continue to Be Growth Driver beyond 2018.NEWS8: A Look into Amgen’s Collaborations in 2H17.NEWS9: Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA.NEWS10: Opdivo Could Be Key Revenue Driver for Bristol-Myers Squibb in 2018.NEWS11: 3 Top-Ranked Drug Stocks That Are Broker Favorites.NEWS12: 3 Top-Ranked Drug Stocks that are Broker Favorites.NEWS13: How Opdivo Is Positioned at the Beginning of 2018.NEWS14: Here’s What’s Moving Novartis And Aeterna Zentaris Right Now.NEWS15: Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA.NEWS16: The Swiss Stock Market Snaps Recent Losing Streak.NEWS17: Biocon Inks Deal With Novartis After U.S. Nod for Biologic Drug.NEWS18: Sandoz Announces Global Collaboration With Biocon - Quick Facts.NEWS19: NVS' Kymriah To Face FDA Again, AEZS Teams Up With SBBP, A Rival For EXAS?.
2018-01-19: NEWS1: Cancer Space Update: Label Expansions, Data Readouts in Focus.NEWS2: Notable ETF Inflow Detected - VEA, NSRGY, NVS, TM.NEWS3: Cancer Space Update: Label Expansions, Data Readouts in Focus.NEWS4: Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion.NEWS5: How Is Bristol-Myers Squibb’s Sprycel Positioned for 2018?.NEWS6: Amgen’s Aimovig is Expected to Witness Steady Growth in 2018.NEWS7: The Swiss Stock Market Climbed Again, But Finishes Week With A Loss.NEWS8: Blog Exposure - FDA Granted Priority Review to Novartis’ Kymriah(TM) for Adults with relapsed/refractory B-cell lymphoma.NEWS9: Pharma Stock Roundup: Merck&apos;s Keytruda Shines in Study, Priority Review for Kymriah Label Expansion.
2018-01-22: NEWS1: Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?.NEWS2: What's in the Cards for Novartis (NVS) This Earnings Season?.NEWS3: Novartis: Erenumab Meets All Endpoints In LIBERTY Migraine Prevention Trial.NEWS4: Behind Novartis’s 4Q17 Estimates: Innovative Medicines.NEWS5: Analyst Ratings and Recommendations for Johnson & Johnson.NEWS6: What&apos;s in the Cards for Novartis (NVS) This Earnings Season?.NEWS7: Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth.NEWS8: These 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition.NEWS9: Inside Novartis’s 4Q17 Earnings: Analyst Estimates.NEWS10: Johnson & Johnson Is Trading at an All-Time High—What’s Next?.NEWS11: The Swiss Stock Market Starts The Week With A Gain - UBS In Focus.NEWS12: These 2 Developments Could Accelerate Johnson & Johnson&apos;s Next Acquisition.NEWS13: Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period.NEWS14: Novartis Closes Tender Offer For Advanced Accelerator Applications.

Answer: Rise